Is ozempic forever? UK surgeon explains how GLP-1 drugs work, and whether you need to take them indefinitely
If you are considering GLP-1 drugs for weight loss, it might be a more serious commitment than you expected. Dr Rajan explains how they work.
Safety and effectiveness of tirzepatide during Ramadan fasting: Real‐world evidence from patients with type 2 diabetes in Bangladesh
Abstract Aims Ramadan fasting poses challenges for patients with type 2 diabetes mellitus (T2DM) due to increased risks of hypoglycemia and metabolic fluctuations. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has shown marked efficacy in glycemic control and weight reduction. This study aimed to evaluate the safety and effectiveness of tirzepatide among Bangladeshi patients with T2DM […]
Unintentional periconceptional exposure to glucagon‐like peptide‐1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan
Abstract Aims To assess whether periconceptional exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with adverse outcomes in women with pregestational type 2 diabetes. Materials and Methods We linked Taiwan’s Birth Certificate Application and National Health Insurance claims (2013–2022) to assemble a nationwide cohort of singleton births to mothers (18–50 years) with pregestational diabetes. […]
Diabetology, Vol. 6, Pages 158: Management of Type 2 and Post-Transplant Diabetes in Kidney Transplant Recipients: A Single-Center Clinical Experience with GLP-1 Receptor Agonists and SGLT-2 Inhibitors
Diabetology, Vol. 6, Pages 158: Management of Type 2 and Post-Transplant Diabetes in Kidney Transplant Recipients: A Single-Center Clinical Experience with GLP-1 Receptor Agonists and SGLT-2 Inhibitors Diabetology doi: 10.3390/diabetology6120158 Authors: Ricardo E. T. Navarrete Joana C. Freitas Isabel Fonseca Ana Cunha Joao Roberto Sa La Salete Martins Objective: The aim was to characterize the […]
Gov’t will assess GLP-1 use for obesity following WHO recommendation
The Health Ministry stated that they will assess the use and funding coverage by the national health insurance …
Doctor issues warning to millions drinking Bailey’s this Christmas – 3 common side effects to watch out for
BAILEY’S and Christmas go hand in hand, and for many, it’s their favourite part of the festive season. But for those who reach for the festive favoured tipple, doctors have issued a strong word of warning. Doctors have issued a warning ahead of the festive season for the many who now use GLP-1 weight-loss medications,…
Alzheimer’s risk could rise with common condition affecting millions, study finds
The first study to evaluate the link between Alzheimer’s disease and body weight found a significant association. Researchers at Washington University Medicine in St. Louis, Missouri, discovered that Alzheimer’s blood biomarkers increased 95% faster in people with obesity than in non-obese individuals. The study, which was presented Tuesday at the annual meeting of the Radiological […]
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi
For Immediate Release Chicago, IL – December 5, 2025 – Today, Zacks Equity Research discusses Eli Lilly LLY, Johnson & Johnson JNJ and Sanofi SNY. Industry: Big Pharma Link: https://www.zacks.com/commentary/2799269/3-large-drug-stocks-to-watch-as-the-industry-shows-some-recovery The drug and biotech sector has recovered in the past couple of months after remaining muted for most of this year. The recovery began with […]
120 Capsules 50-in-1 Natural Activate GLP-1 Supplement only $9.49
Super Hot ~ Lowest EverGet 120 Capsules JonterKing 50-in-1 GLP-1 Supplement with Akkermansia & Vitamin B, GLP Support, Hunger & Metabolism, Natural Activate Probiotic and Prebiotic Formula for only $9.49. Tagged as: 607603459596 | Vitamins & Supplement Click here for complete deal detail and steps on how to get it. Share this deal with your […]
GLP-1RAs shown to reduce risk of cardiovascular death
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide, liraglutide, and tirzepatide are widely prescribed both for Type 2 diabetes and weight loss. These drugs also have shown promise in clinical trials for patients with chronic cardiovascular, kidney, and metabolic diseases. Those studies focused mainly on patients with singular diagnoses, but these conditions often overlap.